The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
32 | 34 | 40 | 27 |
Growth
|
76 | 98 | 43 | 23 |
Safety
|
12 | 13 | 14 | 8 |
Sentiment
|
45 | 94 | 67 | 20 |
|
26 | 30 | 23 | 1 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
86 | 88 | 93 | 5 |
Opinions Change
|
34 | 50 | 50 | 4 |
Pro Holdings
|
n/a | 62 | 38 | 63 |
Market Pulse
|
28 | 84 | 61 | 86 |
Sentiment
|
45 | 94 | 67 | 20 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
32 | 34 | 40 | 27 |
Growth
|
76 | 98 | 43 | 23 |
|
12 | 13 | 14 | 8 |
Combined
|
23 | 1 | 12 | 4 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
58 | 44 | 53 | 23 |
Price vs. Earnings (P/E)
|
65 | 65 | 74 | 52 |
Price vs. Book (P/B)
|
25 | 24 | 31 | 24 |
Dividend Yield
|
28 | 27 | 26 | 21 |
Value
|
32 | 34 | 40 | 27 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
67 | 59 | 52 | 47 |
Profit Growth
|
98 | 100 | 87 | 40 |
Capital Growth
|
28 | 87 | 40 | 27 |
Stock Returns
|
46 | 80 | 13 | 51 |
Growth
|
76 | 98 | 43 | 23 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
9 | 30 | 13 | 14 |
Refinancing
|
16 | 8 | 5 | 19 |
Liquidity
|
55 | 40 | 41 | 14 |
|
12 | 13 | 14 | 8 |
Discover high‑ranked alternatives to Daewoong Pharmaceutical and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.